Zacks: Analysts Anticipate PRA Health Sciences Inc (NASDAQ:PRAH) to Post $1.48 Earnings Per Share

Equities research analysts expect PRA Health Sciences Inc (NASDAQ:PRAH) to announce $1.48 earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for PRA Health Sciences’ earnings, with estimates ranging from $1.46 to $1.50. PRA Health Sciences reported earnings of $1.31 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 13%. The company is expected to report its next quarterly earnings report on Wednesday, February 26th.

On average, analysts expect that PRA Health Sciences will report full year earnings of $5.11 per share for the current fiscal year, with EPS estimates ranging from $5.09 to $5.14. For the next year, analysts forecast that the company will post earnings of $5.82 per share, with EPS estimates ranging from $5.75 to $5.92. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 30th. The medical research company reported $1.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.29 by $0.03. PRA Health Sciences had a return on equity of 27.73% and a net margin of 8.00%. The firm had revenue of $780.70 million for the quarter, compared to analyst estimates of $771.64 million. During the same period last year, the company earned $1.13 earnings per share. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis.

Several equities research analysts have weighed in on PRAH shares. Goldman Sachs Group started coverage on PRA Health Sciences in a research report on Thursday, September 19th. They issued a “buy” rating and a $126.00 target price on the stock. Jefferies Financial Group increased their target price on PRA Health Sciences from $115.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday, September 6th. Wolfe Research raised PRA Health Sciences from a “peer perform” rating to an “outperform” rating and set a $123.00 target price on the stock in a research report on Thursday, November 14th. BidaskClub lowered PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Finally, Zacks Investment Research lowered PRA Health Sciences from a “buy” rating to a “hold” rating and set a $108.00 target price on the stock. in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $115.78.

NASDAQ PRAH traded up $1.41 during trading hours on Friday, hitting $103.46. The company had a trading volume of 856,189 shares, compared to its average volume of 528,280. PRA Health Sciences has a fifty-two week low of $82.12 and a fifty-two week high of $115.50. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 1.65. The business has a fifty day simple moving average of $103.84 and a 200-day simple moving average of $99.23. The firm has a market cap of $6.77 billion, a P/E ratio of 26.31, a price-to-earnings-growth ratio of 1.66 and a beta of 1.13.

Institutional investors and hedge funds have recently modified their holdings of the company. Quadrant Capital Group LLC acquired a new position in shares of PRA Health Sciences during the third quarter valued at $38,000. Pearl River Capital LLC acquired a new position in shares of PRA Health Sciences during the second quarter valued at $40,000. Cullen Frost Bankers Inc. increased its holdings in shares of PRA Health Sciences by 232.5% during the third quarter. Cullen Frost Bankers Inc. now owns 409 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 286 shares during the period. Steward Partners Investment Advisory LLC acquired a new position in shares of PRA Health Sciences during the second quarter valued at $49,000. Finally, CENTRAL TRUST Co increased its holdings in shares of PRA Health Sciences by 20.5% during the third quarter. CENTRAL TRUST Co now owns 792 shares of the medical research company’s stock valued at $79,000 after purchasing an additional 135 shares during the period. 98.60% of the stock is currently owned by institutional investors.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: NASDAQ Stock Market Explained

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.